Literature DB >> 7625808

Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo.

K V Clemons1, M E Homola, D A Stevens.   

Abstract

The activity of the novel triazole SCH 51048 was tested against Coccidioides immitis. SCH 51048 inhibited C. immitis in vitro; MICs for 13 isolates ranged from < or = 0.39 to 0.78 micrograms/ml, and minimum fungicidal concentrations ranged from < or = 0.39 to 1.6 micrograms/ml. In vivo, no mice treated with SCH 51048 at 2 to 50 mg/kg of body weight or 100 mg of fluconazole or itraconazole per kg died of systemic coccidioidomycosis, whereas 60 to 100% of the control mice died. SCH 51048 given at 25 or 50 mg/kg was curative, whereas fluconazole or itraconazole given at 100 mg/kg was not curative. Pharmacokinetic studies showed peak levels in serum of > 14 micrograms/ml, with an estimated half-life of > 12 h. SCH 51048 was 5- to 50-fold or more superior to fluconazole or itraconazole.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7625808      PMCID: PMC162703          DOI: 10.1128/AAC.39.5.1169

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Effect of cyclodextrin on the pharmacology of antifungal oral azoles.

Authors:  J S Hostetler; L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  The new generation of antifungal drugs.

Authors:  D A Stevens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

3.  Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations.

Authors:  R M Tucker; D W Denning; E G Arathoon; M G Rinaldi; D A Stevens
Journal:  J Am Acad Dermatol       Date:  1990-09       Impact factor: 11.527

4.  Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group.

Authors:  J R Graybill; D A Stevens; J N Galgiani; W E Dismukes; G A Cloud
Journal:  Am J Med       Date:  1990-09       Impact factor: 4.965

5.  Efficacy of SCH39304 and fluconazole in a murine model of disseminated coccidioidomycosis.

Authors:  K V Clemons; L H Hanson; A M Perlman; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

6.  Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

7.  Treatment of coccidioidal meningitis with fluconazole.

Authors:  R M Tucker; J N Galgiani; D W Denning; L H Hanson; J R Graybill; K Sharkey; M R Eckman; C Salemi; R Libke; R A Klein
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

8.  Coccidioidomycosis in the acquired immunodeficiency syndrome.

Authors:  D A Bronnimann; R D Adam; J N Galgiani; M P Habib; E A Petersen; B Porter; J W Bloom
Journal:  Ann Intern Med       Date:  1987-03       Impact factor: 25.391

9.  Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses.

Authors:  J N Galgiani; D A Stevens; J R Graybill; W E Dismukes; G A Cloud
Journal:  Am J Med       Date:  1988-03       Impact factor: 4.965

10.  Utility of the triazole D0870 in the treatment of experimental systemic coccidioidomycosis.

Authors:  K V Clemons; D A Stevens
Journal:  J Med Vet Mycol       Date:  1994
View more
  7 in total

Review 1.  Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.

Authors:  K N Sorensen; K V Clemons; D A Stevens
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

2.  Large-Scale Evaluation of In Vitro Amphotericin B, Triazole, and Echinocandin Activity against Coccidioides Species from U.S. Institutions.

Authors:  George R Thompson; Bridget M Barker; Nathan P Wiederhold
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.

Authors:  Perparim Kamberi; Raymond A Sobel; Karl V Clemons; Andreas Waldvogel; Joan M Striebel; Paul L Williams; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

4.  Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis.

Authors:  J E Lutz; K V Clemons; B H Aristizabal; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

5.  Efficacies of two novel azole derivatives each containing a morpholine ring, UR-9746 and UR-9751, against systemic murine coccidioidomycosis.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

6.  In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.

Authors:  J N Galgiani; M L Lewis
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

7.  Nikkomycin Z against Disseminated Coccidioidomycosis in a Murine Model of Sustained-Release Dosing.

Authors:  Gabriele Sass; David J Larwood; Marife Martinez; Paulami Chatterjee; Melissa O Xavier; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2021-07-12       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.